THROMBOCYTOPENIA TREATMENT MARKET ANALYSIS

Thrombocytopenia Treatment Market, By Drug Class (Glucocorticoids, Lysosomal Enzyme, and Platelet Stimulating Agent), and By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI1484
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Thrombocytopenia Treatment Market Dynamics

The thrombocytopenia treatment market is driven by increasing prevalence of thrombocytopenia globally. The risk of developing thrombocytopenia is much higher for chronic Hepatitis C cases. In 2014, according to World Health Organization (WHO), the prevalence of Hepatitis C was lower in Americas and Europe as compared to Africa and Pakistan, where the prevalence of chronic liver disorder was 4-6 % higher than that in Americas and Europe. Liver disease has become a socio economic and global health problem, as 60-80% of the population develops the disease. Furthermore, increasing government support for fast-track approval to discover newer treatments for this disorder and increasing investment in the development of new drugs by biotechnology and pharmaceutical companies are expected to propel growth of the thrombocytopenia treatment market during the forecast period. However, from 2023, thrombocytopenia treatment market is projected to witness a slowdown in growth due to patent expiration and increasing availability of generics of Promacta and MabThera.